Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Overview 11 Therapeutics Development 12 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Stage of Development 12 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Therapy Area 13 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Indication 14 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Companies 17 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Universities/Institutes 21 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Companies Involved in Therapeutics Development 29 Ablynx NV 29 Agilvax, Inc. 30 Aridis Pharmaceuticals LLC 31 Bavarian Nordic A/S 32 Celltrion, Inc. 33 Emergent BioSolutions Inc. 34 F. Hoffmann-La Roche Ltd. 35 Gene Techno Science Co., Ltd. 36 GenVec, Inc. 37 Gilead Sciences, Inc. 38 GlaxoSmithKline Plc 39 iBio, Inc. 40 Johnson & Johnson 41 mAbxience S.A. 42 MedImmune, LLC 43 Medivir AB 44 Mucosis B.V. 45 Navigen Pharmaceuticals, Inc. 46 Novavax, Inc. 47 Regeneron Pharmaceuticals, Inc. 48 Takeda Pharmaceutical Company Limited 49 The International Biotechnology Center (IBC) Generium 50 Vaxart, Inc. 51 VLP Biotech, Inc. 52 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Drug Profiles 53 (human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 (influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 AK-0529 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 ALX-0171 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 AR-201 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 GNR-007 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 GV-2311 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 JNJ-61187165AAA - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 JNJ-61187191AAA - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 MEDI-7510 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 MEDI-8897 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 MVA-RSV - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 palivizumab biosimilar - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 palivizumab biosimilar - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 palivizumab biosimilar - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 palivizumab biosimilar - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 palivizumab biosimilar - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 presatovir - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 respiratory syncytial virus (virus like particle) vaccine - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 respiratory syncytial virus (virus like particle) vaccine - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 respiratory syncytial virus (virus like particle) vaccines - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 respiratory syncytial virus immune globulin (human) - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 respiratory syncytial virus vaccine - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 respiratory syncytial virus vaccine - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 respiratory syncytial virus vaccine - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 respiratory syncytial virus vaccine - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 respiratory syncytial virus vaccine - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 respiratory syncytial virus vaccine - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 respiratory syncytial virus vaccine - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 respiratory syncytial virus vaccine - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 respiratory syncytial virus vaccine - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 RSV-001 - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 RV-521 - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 suptavumab - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 SynGEM - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Dormant Projects 107 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Discontinued Products 108 Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Featured News & Press Releases 109 Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program 109 May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults 110 May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations 111 May 03, 2016: Ablynx reports positive top line results for its inhaled Anti-RSV Nanobody (ALX-0171) in a phase I/IIa Study in infants hospitalised with a RSV infection 111 Mar 09, 2016: First consortium of local manufacturers to make affordable biosimilars available for low income countries 113 Mar 04, 2016: Immune Design’s GLAAS Platform Shown to Modulate the Allergic Immune Response 113 Jan 20, 2016: Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London 114 Dec 21, 2015: Novavax Appoints Mark Twyman Vice President Marketing 115 Dec 17, 2015: Ablynx Completes Enrolment Of The First-In-Infant Phase I/IIa Safety Study With Its Anti-RSV Nanobody And Extends The Trial For Younger Infants 115 Dec 14, 2015: Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults 116 Dec 03, 2015: Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization 116 Nov 19, 2015: Vaxart Presents Positive Preclinical Data for Oral RSV Vaccine at RSV Vaccines for the World Conference 117 Nov 16, 2015: Novavax to Make Multiple Presentations at RSV Vaccines for the World 118 Nov 09, 2015: Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults 118 Oct 29, 2015: MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design's GLAAS Discovery Platform 119 Appendix 120 Methodology 120 Coverage 120 Secondary Research 120 Primary Research 120 Expert Panel Validation 120 Contact Us 120 Disclaimer 121

List of Tables Number of Products under Development for, H1 2016 12 Number of Products under Development by Therapy Area, H1 2016 13 Number of Products under Development by Indication, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Number of Products under Investigation by Universities/Institutes, H1 2016 21 Products under Investigation by Universities/Institutes, H1 2016 22 Assessment by Monotherapy/Combination Products, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Pipeline by Ablynx NV, H1 2016 29 Pipeline by Agilvax, Inc., H1 2016 30 Pipeline by Aridis Pharmaceuticals LLC, H1 2016 31 Pipeline by Bavarian Nordic A/S, H1 2016 32 Pipeline by Celltrion, Inc., H1 2016 33 Pipeline by Emergent BioSolutions Inc., H1 2016 34 Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 35 Pipeline by Gene Techno Science Co., Ltd., H1 2016 36 Pipeline by GenVec, Inc., H1 2016 37 Pipeline by Gilead Sciences, Inc., H1 2016 38 Pipeline by GlaxoSmithKline Plc, H1 2016 39 Pipeline by iBio, Inc., H1 2016 40 Pipeline by Johnson & Johnson, H1 2016 41 Pipeline by mAbxience S.A., H1 2016 42 Pipeline by MedImmune, LLC, H1 2016 43 Pipeline by Medivir AB, H1 2016 44 Pipeline by Mucosis B.V., H1 2016 45 Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 46 Pipeline by Novavax, Inc., H1 2016 47 Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 48 Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 49 Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 50 Pipeline by Vaxart, Inc., H1 2016 51 Pipeline by VLP Biotech, Inc., H1 2016 52 Dormant Projects, H1 2016 107 Discontinued Products, H1 2016 108 List of Figures Number of Products under Development for, H1 2016 12 Number of Products under Development by Therapy Area, H1 2016 13 Number of Products under Development by Indication, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 23 Number of Products by Stage and Mechanism of Actions, H1 2016 24 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 27

Ablynx NV Agilvax, Inc. Aridis Pharmaceuticals LLC Bavarian Nordic A/S Celltrion, Inc. Emergent BioSolutions Inc. F. Hoffmann-La Roche Ltd. Gene Techno Science Co., Ltd. GenVec, Inc. Gilead Sciences, Inc. GlaxoSmithKline Plc iBio, Inc. Johnson & Johnson mAbxience S.A. MedImmune, LLC Medivir AB Mucosis B.V. Navigen Pharmaceuticals, Inc. Novavax, Inc. Regeneron Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited The International Biotechnology Center (IBC) Generium Vaxart, Inc. VLP Biotech, Inc.